Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 5/20 | 0.38 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 0.38 |
| ▸ | PDE4A | P27815 | 5/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9873196 | 0.93 | PDE7A (0.40) | PDE7APDE7BPDE4APDE4BPDE4C | |
| SCHEMBL9873032 | 0.92 | AGTR1 (0.34) | AGTR1AGTR2 | |
| SCHEMBL9874535 | 0.89 | PPARG (0.33) | — | |
| SCHEMBL9872957 | 0.89 | PDE4A (0.38) | PDE7APDE7BPDE4APDE4BPDE4C | |
| SCHEMBL9871840 | 0.89 | AGTR1 (0.32) | AGTR1AGTR2 | |
| SCHEMBL9873778 | 0.88 | AGTR1 (0.33) | AGTR1AGTR2 | |
| SCHEMBL9874661 | 0.86 | AGTR2 (0.35) | AGTR2 | |
| SCHEMBL9874995 | 0.86 | AGTR1 (0.35) | PDE7APDE7BPDE4APDE4BPDE4C | |
| SCHEMBL9873149 | 0.86 | AGTR1 (0.46) | AGTR1AGTR2 | |
| SCHEMBL9873077 | 0.86 | AGTR1 (0.35) | PDE3BPDE3AAGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1991019715-A1 | 1H-SUBSTITUTED-IMIDAZO[4,5-d]PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-12-26 | — | — | WO | disclosed |